Cagrilintide and CagriSema

What it is

Cagrilintide is a long-acting analogue of the hormone amylin. “CagriSema” is Novo Nordisk's name for its investigational cagrilintide–semaglutide development program and proposed fixed-dose combination product.

The published REDEFINE trials coadministered defined sponsor study products under controlled protocols. REDEFINE 1 used a double-dummy, two-injection design. That distinction matters: trial evidence applies to the identified study products and conditions, not automatically to separately obtained ingredients, an online blend, a compounded preparation, or a do-it-yourself mixture.

Why people care

CagriSema has produced large weight-management trials and is often discussed alongside approved GLP-1 medicines. The useful question is not simply whether both ingredient names appear. It is what the identified study products showed, for whom, compared with what, and whether those findings apply to the product being discussed.

What humans actually show

• REDEFINE 1: A 68-week phase 3a trial randomized 3,417 adults with overweight or obesity and without diabetes. The estimated mean body-weight change was −20.4% with cagrilintide-semaglutide and −3.0% with placebo.
• REDEFINE 2: A 68-week phase 3a trial randomized 1,206 adults with overweight or obesity and type 2 diabetes. Mean body-weight change was −13.7% with cagrilintide-semaglutide and −3.4% with placebo.
• REDEFINE 5: A 68-week phase 3a trial randomized 331 adults in Japan and Taiwan with overweight or obesity, with or without type 2 diabetes. Mean body-weight change was −18.4% with coadministered cagrilintide and semaglutide and −11.9% with the defined semaglutide comparator.
• Earlier phase 2 evidence: A 32-week trial randomized 92 adults with type 2 diabetes. HbA1c change was greater with CagriSema than cagrilintide but was not statistically different from semaglutide in the reported primary analysis.
• REDEFINE 4 boundary: Novo Nordisk reported sponsor topline results from an open-label comparison with tirzepatide in February 2026. The trial did not meet its primary noninferiority endpoint. PepCurrent did not identify a peer-reviewed results paper in the July 26 review, so this remains sponsor-reported topline evidence and cannot support a universal ranking.

Mechanistic and nonhuman evidence

Cagrilintide's amylin-based mechanism helps explain why it is being studied with semaglutide. Mechanism does not establish clinical benefit, interaction safety, product identity, or equivalence to the sponsor's study products. The core conclusions here come from human trials and official regulatory records.

FDA and U.S. status

Novo Nordisk announced that it submitted a CagriSema New Drug Application to FDA on December 18, 2025 for weight management and said FDA was expected to review the application in 2026. Submission is not approval. PepCurrent identified no FDA approval action for CagriSema in the July 26 review.

FDA states that cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. FDA warning letters have described cagrilintide and cagrilintide–semaglutide products marketed online in the United States as unapproved new drugs.

Risks and warning limits

Gastrointestinal adverse events were frequent in the pivotal trials. REDEFINE 1 reported them in 79.6% of the cagrilintide-semaglutide group and 39.9% of the placebo group; REDEFINE 2 reported 72.5% and 34.4%, respectively. The papers described the events as mainly transient and mild to moderate.

CagriSema has no FDA-approved prescribing information. Its final indication, contraindications, warnings, manufacturing controls, and benefit-risk language cannot be assumed before FDA action and final labeling. In a March 2026 Wegovy approval letter, FDA required a future trial of two semaglutide strengths, both combined with cagrilintide, with dysesthesia as an adverse event of special interest. That requirement records a question to study; it is not a CagriSema result, incidence estimate, causal conclusion, or final warning.

What remains unknown

• Whether and how FDA will act on the submitted application.
• The final approved formulation, indication, contraindications, warnings, and postmarketing obligations, if approval occurs.
• Full peer-reviewed results from REDEFINE 4.
• Safety, stability, sterility, concentration, and clinical performance of any unrelated product or separately mixed ingredients.

Product identity and quality limits

The trials establish findings for defined sponsor study products used under controlled protocols. They do not authenticate an online blend, compounded preparation, separately obtained ingredient, or product carrying a similar name. Evidence does not transfer because the products, formulation, quality controls, stability, sterility, handling, and protocol are not established.

An FDA substance identifier or UNII is an identity record, not an approval. Approval of defined semaglutide products does not approve cagrilintide, CagriSema, or an unrelated semaglutide-containing mixture.

What has been studied together

Direct human evidence exists for coadministration of defined cagrilintide and semaglutide study products. That is different from a general interaction or compatibility finding for every product sold under those ingredient names. “No separately published interaction study found” would not mean a separately mixed product is safe.

PepCurrent does not provide dosing, sourcing, switching, or personalized treatment advice.

What people are hearing

• “Phase 3 means it is basically approved.” It does not. Trial publication, application submission, FDA review, approval, and final labeling are separate events.
• “Using cagrilintide and semaglutide together is basically CagriSema.” Two ingredient names do not establish the sponsor's product, formulation, quality controls, stability, sterility, handling, or study protocol.
• “The trials prove it is better than every alternative.” The published trials support only their defined populations, comparators, durations, and outcomes. They do not support a universal ranking.

Questions readers raise

Readers often ask whether phase 3 means approval, whether separate ingredients reproduce CagriSema, and whether the program can be ranked against semaglutide or tirzepatide. These questions identify claims to check; they are not evidence of efficacy, safety, or popularity.

PepCurrent has not published anecdotal theme counts or public user reviews for this profile. Self-reports would be limited by selection bias, unknown product identity, concurrent medications and behaviors, and unverifiable outcomes.

What would change this answer

• An FDA approval, complete response, or other official action would change the dated U.S. regulatory status.
• Final FDA labeling, if approved, would define the approved product, use, warnings, and conditions.
• A peer-reviewed REDEFINE 4 report could support a scoped comparison for its defined population and outcome.
• Product-level evidence would be required to authenticate any product outside the sponsor's study and regulatory record.

Sources and records

• Garvey et al., 2025 — REDEFINE 1 phase 3a trial
• Davies et al., 2025 — REDEFINE 2 phase 3a trial
• Yamauchi et al., 2026 — REDEFINE 5 phase 3a trial
• Frias et al., 2023 — phase 2 coadministration trial
• ClinicalTrials.gov — REDEFINE 1, NCT05567796
• FDA concerns with unapproved GLP-1 drugs
• FDA warning letter concerning cagrilintide products
• FDA Wegovy higher-dose approval letter, March 2026
• FDA substance record — cagrilintide
• Novo Nordisk — CagriSema NDA submission, December 2025
• Novo Nordisk — REDEFINE 4 sponsor topline, February 2026

Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.